ACTIVARMOR, INC.

ActivArmor, Inc. specializes in the research, design, and rapid manufacturing of personalized orthopedic braces and splints for military medical applications, leveraging advanced materials science and patient-specific biomechanical modeling. Their technical expertise lies in additive manufacturing, thermoplastic composite fabrication, and clinical workflow integration for musculoskeletal injury management in operational environments. The company differentiates itself through its ability to translate battlefield medical needs into scalable, on-demand production systems that reduce lead times and improve functional outcomes for service members. Their approach combines patient data acquisition, digital templating, and rapid prototyping to deliver custom-fitted medical devices directly aligned with Department of Defense operational medicine requirements. ActivArmor has demonstrated direct engagement with the Department of Defense, specifically through the Defense Health Agency’s Small Business Innovation Research program, where they delivered a Phase II proposal focused on accelerating the deployment of personalized orthotic devices for combat casualty care. This relationship reflects a targeted alignment with military medical R&D priorities, particularly in trauma response and field-deployable medical solutions. The contractor’s primary industry focus is in Research and Development in the Physical, Engineering, and Life Sciences, where they apply engineering design principles to clinical orthopedic challenges. Their vertical specialization is in point-of-care medical device innovation for defense and trauma care settings, positioning them at the intersection of biomedical engineering and military operational medicine. ActivArmor, Inc. is a Women-Owned Small Business headquartered in Port Saint Lucie, Florida, with a lean, agile structure optimized for responsive R&D and prototype-to-production transitions. Their WOSB certification underscores their commitment to diversity in federal contracting and enhances their access to targeted set-aside opportunities within defense and health innovation markets.